Rubella virus IgG ELSIA kit

Sample

Serum, plasma

Species Reactivity

Human

Detection Method

iELISA

Intended Use

This product is used for the in vitro qualitative detection of rubella virus IgG antibodies in human serum/plasma or whole blood samples.

Contents of Kit

1. Pre-coated plate: 12T×8, inactivated purified rubella virus antigen
2. Mouse anti-human IgG monoclonal antibody enzyme label: 10mlx1 bottle, HRP enzyme-labeled
3. Mouse anti-human IgG monoclonal antibody, containing stabilizer and biological preservatives
4. Concentrated washing solution (20×): 30ml×1 bottle, 20 times concentrated phosphate buffer, containing NaCl, Tween-20
5. Sample diluent: 50ml×1 bottle, buffer, stabilizer, etc.
6. Negative control substance: 0.5ml×1 bottle, inactivated human rubella virus IgG antibody negative serum, stabilizer
7. Positive control substance: 0.5ml×1 bottle, inactivated human rubella virus IgG antibody positive serum, stabilizer
8. Substrate A: 5.0ml×1 bottle, the main component is carbamide peroxide
9. Substrate B: 5.0ml×1 bottle, the main component is TMB
10. Stop solution: 5.0ml×1 bottle, 0.5M H₂SO₄ solution
11. Ziplock bag: 1 serving
12. Parafilm: 3 sheets

Storage

1. Store refrigerated at 2-8°C and away from light. Freezing is prohibited. The validity period is 12 months.
2. Unused pre-coated boards should be immediately put into a ziplock bag with desiccant and sealed, and the storage time at 2-8°C should not exceed one week.
3. Any unused reagents of other components should be capped immediately and stored in an environment of 2-8°C. The storage time should not exceed one week.
4. Please refer to the product label for the production date and expiration date of the product.

General Description

Suitable for auxiliary diagnosis of rubella virus infection.
Rubella virus is an enveloped virus belonging to the Rubellaviridae family. It has only one serotype and has no cross-reactivity with other enveloped viruses. Rubella is an acute viral infection that generally affects only susceptible children and young adults worldwide. The occurrence of rubella is seasonal, with epidemics occurring every 5 to 9 years. The degree and periodicity of the epidemic are different in developed and developing countries, which may be related to the different immunization status of each country. Before the launch of large-scale rubella vaccination, the average age of children infected with rubella was 2 to 12 years old. Rubella virus spreads through the respiratory tract. It initially replicates in the nasopharyngeal mucosa and local lymph nodes. The incubation period is 12 to 23 days. The clinical symptoms of rubella are like those of a common cold. It usually begins with symptoms of upper flu and swollen lymph nodes behind the ears and suboccipital lymph nodes. Later, a latent red maculopapular rash appears on the face and quickly spreads throughout the body. Infection during pregnancy may cause fetal death or congenital rubella syndrome.
Antibodies can be detected 14 to 18 days after rubella virus infection, at which time maculopapular rash appears approximately simultaneously. Both lgM and lgG antibody titers initially increased, and then lgG continued to be at a higher titer, while lgM antibody titers decreased rapidly. The lgG level reached a peak 4 to 6 weeks after infection, and then gradually dropped to a certain level. Lasts a lifetime.
At present, the clinical and laboratory detection methods of rubella virus IgG mainly include indirect hemagglutination inhibition test, latex agglutination test, enzyme-linked immunosorbent assay, one-way radial hemolysis test and fluorescence inhibition test.